Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ELEV
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.37
vs -0.86
Q3.23
N/A
-0.25
vs -1.67
Q4.23
N/A
-0.19
vs -0.82
Q1.24
N/A
-0.23
vs -0.50
Q2.24
N/A
-0.18
vs -0.37
Q3.24
N/A
-0.22
vs -0.25
Q4.24
N/A
-0.18
vs -0.19
Q1.25
N/A
-0.24
vs -0.23
Q2.25
N/A
-0.22
vs -0.18
Q3.25
N/A
-0.13
vs -0.22
Sales Growth
YoY
Current
Estimates
Q4.22
NA
NA vs NA
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
58K vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
-100%
NA vs 58K
Q1.25
NA
NA vs NA
Return on Equity
QoQ
Q2.23
-14%
-0.14
vs -0.51
Q3.23
-17%
-0.17
vs -0.14
Q4.23
-14%
-0.14
vs -0.17
Q1.24
-14%
-0.14
vs -0.14
Q2.24
-13%
-0.13
vs -0.14
Q3.24
-19%
-0.19
vs -0.13
Q4.24
-17%
-0.17
vs -0.19
Q1.25
-30%
-0.30
vs -0.17
Institutionnal Ownership
QoQ
Q2.23
40
40
vs 27
48%
Q3.23
40
40
vs 40
NA
Q4.23
31
31
vs 40
-22%
Q1.24
64
64
vs 31
106%
Q2.24
81
81
vs 64
27%
Q3.24
69
69
vs 81
-15%
Q4.24
72
72
vs 69
4%
Q1.25
72
72
vs 72
NA
prnewswire.com
7 hours ago
prnewswire.com
13 hours ago
Quote Panel
Key Metrics
Relative Strength
ELEV
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
NASDAQ
Unprofitable
Unprofitable
0.00 ( 0.97%)
Relative Strenght
4
Volume Buzz
-53%
Earning Acce
No
Dist 52w H.
88%Forecast
-113%2026-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Hold
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
H.C. Wainwright
downgradePrevious: Not converted
2025-06-10
Now: Neutral
Citigroup
downgradePrevious: Not converted
2025-03-21
Now: Market Perform
Wedbush
downgradePrevious: Not converted
2025-03-20
Now: Neutral
William Blair
initialisePrevious: Not converted
2025-01-03
Now: Outperform
